Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities-Reference-Cited by-同舟云学术

Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities

Published:2020-04-24 Issue:1 Volume:374 Page:24-37
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Ozoux Marie-Laure,Briand Véronique,Pelat Michel,Barbe Fabrice,Schaeffer Paul,Beauverger Philippe,Poirier Bruno,Guillon Jean-Michel,Petit Frédéric,Altenburger Jean-Michel,Bidouard Jean-Pierre,Janiak Philip

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference50 articles.

1. The Angiotensin Type 1 Receptor Antagonist, Eprosartan, Attenuates the Progression of Renal Disease in Spontaneously Hypertensive Stroke-Prone Rats with Accelerated Hypertension

2. Altenburger J-M Fossey V Janiak P Lassalle G Petit F Vernières J-C (2008) inventors, Sanofi Aventis, assignee. 5,6-Bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists. 21/02/2008 Patent WO 2008/020124 A1.

3. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

4. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction

5. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Urotensin II system in chronic kidney disease;Current Research in Physiology;2024

2. PRESCRIPTION PATTERN OF ANTIBIOTICS AND THEIR APPROPRIATENESS IN PATIENTS WITH CHRONIC KIDNEY DISEASE-AN OBSERVATIONAL STUDY IN A TERTIARY CARE TEACHING HOSPITAL IN SOUTH INDIA;International Journal of Current Pharmaceutical Research;2023-01-15

3. Combination of Docking-Based and Pharmacophore-Based Virtual Screening Identifies Novel Agonists That Target the Urotensin Receptor;Molecules;2022-12-08

4. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors;Current Diabetes Reviews;2022-08-16

5. Buddleoside inhibits TLR4-related pathway in a mouse model of acute liver failure, promotes autophagy, and inhibits inflammation;Tropical Journal of Pharmaceutical Research;2022-05-28